JP2019534247A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534247A5 JP2019534247A5 JP2019512681A JP2019512681A JP2019534247A5 JP 2019534247 A5 JP2019534247 A5 JP 2019534247A5 JP 2019512681 A JP2019512681 A JP 2019512681A JP 2019512681 A JP2019512681 A JP 2019512681A JP 2019534247 A5 JP2019534247 A5 JP 2019534247A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nrp
- amino acid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010027476 Metastases Diseases 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000007124 immune defense Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383243P | 2016-09-02 | 2016-09-02 | |
| US62/383,243 | 2016-09-02 | ||
| US201762492019P | 2017-04-28 | 2017-04-28 | |
| US62/492,019 | 2017-04-28 | ||
| PCT/US2017/050072 WO2018045371A2 (en) | 2016-09-02 | 2017-09-05 | nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534247A JP2019534247A (ja) | 2019-11-28 |
| JP2019534247A5 true JP2019534247A5 (https=) | 2020-10-15 |
Family
ID=61309026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512681A Pending JP2019534247A (ja) | 2016-09-02 | 2017-09-05 | ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10857201B2 (https=) |
| EP (1) | EP3506924A4 (https=) |
| JP (1) | JP2019534247A (https=) |
| KR (1) | KR20190045271A (https=) |
| CN (1) | CN109937047A (https=) |
| AU (1) | AU2017321965A1 (https=) |
| BR (1) | BR112019004299A2 (https=) |
| CA (1) | CA3035770A1 (https=) |
| MX (1) | MX2019002479A (https=) |
| RU (1) | RU2019109049A (https=) |
| SG (1) | SG11201901830UA (https=) |
| WO (1) | WO2018045371A2 (https=) |
| ZA (1) | ZA201901942B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11324801B2 (en) | 2016-09-02 | 2022-05-10 | University Of Utah Research Foundation | NNIF and nNIF-related peptides and related methods |
| US20230158108A1 (en) * | 2020-05-04 | 2023-05-25 | University Of Utah Research Foundation | Immunothrombosis in covid-19 acute respiratory distress syndrome |
| CN117004744B (zh) * | 2022-04-27 | 2024-05-24 | 数字碱基(南京)科技有限公司 | 一种基于血浆微生物dna特征的肺癌预后评估方法及模型 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
| US9308235B2 (en) * | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| EP4219534A3 (en) * | 2013-07-08 | 2023-09-27 | The University of Utah Research Foundation | Methods for treatment of and prophylaxis against inflammatory disorders |
-
2017
- 2017-09-05 SG SG11201901830UA patent/SG11201901830UA/en unknown
- 2017-09-05 CN CN201780067221.2A patent/CN109937047A/zh active Pending
- 2017-09-05 BR BR112019004299A patent/BR112019004299A2/pt not_active IP Right Cessation
- 2017-09-05 JP JP2019512681A patent/JP2019534247A/ja active Pending
- 2017-09-05 AU AU2017321965A patent/AU2017321965A1/en not_active Abandoned
- 2017-09-05 WO PCT/US2017/050072 patent/WO2018045371A2/en not_active Ceased
- 2017-09-05 US US16/328,697 patent/US10857201B2/en active Active
- 2017-09-05 EP EP17847679.2A patent/EP3506924A4/en not_active Withdrawn
- 2017-09-05 MX MX2019002479A patent/MX2019002479A/es unknown
- 2017-09-05 RU RU2019109049A patent/RU2019109049A/ru unknown
- 2017-09-05 KR KR1020197009122A patent/KR20190045271A/ko not_active Ceased
- 2017-09-05 CA CA3035770A patent/CA3035770A1/en active Pending
-
2019
- 2019-03-28 ZA ZA2019/01942A patent/ZA201901942B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521983A5 (https=) | ||
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| JPWO2019107530A5 (https=) | ||
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| CY1123304T1 (el) | Αναστολη πεπτιδιων που προερχονται απο μεταγραφημα 1 τυπου trem (tlt-1) και χρησεις αυτωn | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| JP2017158561A5 (https=) | ||
| WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| JP2019534247A5 (https=) | ||
| JP2017221201A5 (https=) | ||
| JP2012115277A5 (https=) | ||
| SA518400460B1 (ar) | مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها | |
| CY1123014T1 (el) | Αναστολη των πεπτιδιων που προερχονται απο τον υποδοχεα ενεργοποιησης που εκφραζεται σε μυελοειδη κυτταρα-1 (trem-1) και το μεταγραφο τυπου trem 1 (tlt-1) και χρησεις αυτων | |
| JP2019533722A5 (https=) | ||
| MX388822B (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| JP2019513752A5 (https=) | ||
| JPWO2019156137A5 (https=) | ||
| NZ708990A (en) | Method for activating helper t cell | |
| ZA202201828B (en) | Therapeutic fusion proteins | |
| CN110799522A (zh) | 用于治疗、改善或预防脑出血的肽及其用途 | |
| JP2012102105A5 (https=) | ||
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| JP2018529626A5 (https=) | ||
| MX2014000204A (es) | Metodo de administracion y tratamiento. | |
| WO2010103515A3 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases |